Biogen, the state’s largest local drug company by market cap and headcount, is about to lose yet another top executive.
Kenneth DiPietro plans to step down as executive vice president of human resources tomorrow, a spokesman for the Cambridge drugmaker told the Boston Business Journal on Thursday. DiPietro took on that role in January 2012 following stints at tech giants Lenovo Group, Microsoft (Nasdaq: MSFT) and Dell.
It’s not immediately clear what DiPietro plans on doing after he leaves Biogen. He also serves on the board of Cambridge medical device firm InVivo Therapeutics.
DiPietro will be the latest top official to leave Biogen (Nasdaq: BIIB) or take a diminished role. Chief scientific officer Spyros Artavanis-Tsakonas recently changed titles to part-time visiting scientist while he conducts lab research — partly funded by Biogen — at Harvard Medical School. In March, Adriana Karaboutis left her post as executive vice president of technology, business solutions and corporate affairs.
Previous C-suite departures include R&D head Doug Williams, commercial operations leader Tony Kingsley, corporate development and strategy chief Adam Koppel, and chief information officer Matt Griffiths,. The most high-profile move occurred in January, when longtime CEO George Scangos was replaced by Michel Vounatsos.
The wave of departures comes as Biogen confronts an uncertain future. The company has seen tepid growth in its multiple sclerosis franchise, placing added pressure on its newly-launched infant disease drug Spinraza, as well as on a promising neuroscience pipeline that includes late-stage Alzheimer’s treatment aducanumab.
While rumors about a potential acquisition of Biogen have seemed to subside recently, the company has shown a renewed appetite for dealmaking of its own. In April, it licensed an experimental Alzheimer’s drug from Bristol-Myers Squibb for $300 million. And on May 15, Biogen shelled out $120 million for a stroke treatment that is ready for Phase 3 trials.
Source: Boston Business Journal
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.